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ttp://dx.doi.org/10.1016/j.jmoldx.2013.01.003The Guthrie 903 card archived dried blood spots (DBSs) are a unique but terminal resource amenable for
individual and population-wide genomic proﬁling. The limited amounts of DBS-derived genomic DNA
(gDNA) can be whole genome ampliﬁed, producing sufﬁcient gDNA for genomic applications, albeit
with variable success; optimizing the isolation of high-quality DNA from these ﬁnite, low-yield spec-
imens is essential. Agarose gel electrophoresis and spectrophotometry are established postextraction
quality control (QC) methods but lack the power to disclose detailed structural, qualitative, or quan-
titative aspects that underlie gDNA failure in downstream applications. Visual automated ﬂuorescence
electrophoresis (VAFE) is a novel QC technology that affords precise quality, quantity, and molecular
weight of double-stranded DNA from a single microliter of sample. We extracted DNA from 3-mm DBSs
archived in the Swedish Neonatal Repository for >30 years and performed the ﬁrst quantitative and
qualitative analyses of DBS-derived DNA on VAFE, before and after whole genome ampliﬁed, in parallel
with traditional QC methods. The VAFE QC data were correlated with subsequent sample performance in
PCR, sequencing, and high-density comparative genome hybridization array. We observed improved
standardization of nucleic acid quantity, quality and integrity, and high performance in the downstream
genomic technologies. Addition of VAFE measures in QC increases conﬁdence in the validity of genetic
data and allows cost-effective downstream analysis of gDNA for investigational and diagnostic appli-
cations. (J Mol Diagn 2013, 15: 283e290; http://dx.doi.org/10.1016/j.jmoldx.2013.01.003)Supported by National Institute of Neurological Disorders and Stroke
grants NS067013 and NS067013S (A.M.G.), NS049130, and NS076916
(J.L.N.); Citizens United for Research in Epilepsy; Fiorito Foundation and
the Emma Bursick Memorial Fund (A.M.G.); the Blue Bird Circle Foun-
dation (J.L.N.); and the Stockholm County Council, Regional Agreement
on Medical Training and Clinical Research (T.T. and O.S.)
Disclosures: Agilent Technologies loaned the Agilent 2200 TapeStation
and gave access to the prototype Agilent Genomic DNA ScreenTape.Sudden unexpected death in epilepsy (SUDEP) is the most
common cause of mortality in people with seizure disorders,
and the mechanisms of SUDEP are incompletely understood.
Candidate molecular risk factors include defects in ion channel
genes linked to long QT syndrome,1 epilepsy,2 and genes of
the serotonergic pathways involved in arousal and respiration.3
Precision molecular autopsy4,5 and diagnostics,6,7 as well as
personalized or familial risk prediction8e11 based on candidate
gene proﬁling, are critically dependent on the availability of
representative high-quality tissue samples.12 However, pro-
curement of postmortem biological specimens often poses
logistical, ethical, or cultural obstacles.13e15stigative Pathology
.The Guthrie 903 card archived dried blood spots (DBSs) are
an established enduring medium frequently collected by
neonatal registries and forensic laboratories.16,17 They are
a unique resource amenable for individual and population-wide
Klassen et algenomic proﬁling,18e21 considering the easy and cost-effective
specimen collection, simple and stable long-term storage, and
straightforward processing in nucleic acid extraction.15,22 In
cases of sudden death among otherwise healthy individuals, the
DBSs collected at birth may become the sole high-quality
genomic sample to allow molecular autopsy, personalized
diagnostics, and familial risk prediction.13,23 Because theDBSs
represent a nonrenewable reserve, they require judicious allo-
cation to projects of considerable public health impact with
well-informed methods that maximize the source utility.17,18,22
Currently, the actual DBS-derived DNA performance often
ﬂuctuates disproportionately to the qualitative and quantitative
values predicted by the established methods of gel electro-
phoresis and spectrophotometry, respectively.15,22,24 More-
over, the visual estimate of DNA integrity derived from
agarose gel is imprecise and consumes much of the precious
original specimen. A new visual automated ﬂuorescence
electrophoresis (VAFE) technology used by the Agilent 2200
TapeStation (Agilent Technologies, Inc., Santa Clara, CA)
enables precise and visible postextraction quality control (QC)
of nucleic acids, including high-molecular-weight genomic
DNA (gDNA). It allows qualitative and quantitative stan-
dardization of nucleic acids before their terminal commitment
to downstream diagnostic or proﬁling technologies while
requiring a negligible amount of DNA for accurate molecular
characterization of the template. This translates into cost-
effective use of the analytical platforms and increased conﬁ-
dence in the validity of the ﬁnal genomic data.
We successfully extracted serial gDNA samples from 16
individual 3-mm DBSs collected on Guthrie 903 cards and
deposited at room temperature in the Swedish Repository
for 30 years. We performed the ﬁrst systematic combined
quantitative and qualitative analysis of aged archived DBS-
derived DNA with VAFE before and after whole genome
ampliﬁcation (WGA)25,26 and in parallel to our extant,
traditional methodsebased QC paradigm (Figure 1A).15
Finally, we correlated the novel postextraction DNA QC
with sample performance in PCR, sequencing, and a high-
density comparative genome hybridization array.
Materials and Methods
DBS Samples
The Swedish Repository of DBS samples collected on
Guthrie 903 cards for neonatal screening of inborn diseases
provided 2  3-mm blood spot punches in deidentiﬁed
sterile microfuge tubes. There were total of 16 samples
representing two decades: the 1970s (1975, 1976, 1977, and
1978) and the 1980s (1980, 1982, 1984, and 1986).
gDNA Extraction from 3-mm Blood Spot
A single 3-mm DBS from each sample was transferred to
a fresh 1.5-mL microfuge tube. Using the QiaAmpMini Spin
Kit (Qiagen, Hilden, Germany), gDNA was extracted284according to the manufacturer’s protocol for DBSs. In brief,
the DBS was incubated for 10 minutes at 85C in buffer ATL
and then proteinase K solution was added. The sample was
vortexed and incubated for 1 hour at 56C to facilitate enzy-
matic digestion of the sample. Buffer AL was then added, the
sample was incubated at 70C for 10 minutes, absolute
ethanol was added, and the sample was vortexed thoroughly
to mix. The supernatant solution was applied to the QIAamp
mini spin column andwas bound to the column via a 1-minute
centrifugation at 6000  g. Filtrate was discarded, and the
sample was washed on the column by the application of buffer
AW1, followed by a 1-minute 6000 g spin where the ﬁltrate
was discarded. Buffer AW2 was then applied, the sample was
spun at 20,000 g for 3minutes, theﬁltratewas discarded, and
the spin columnwas centrifuged again for 1minute at 20,000
g to remove all trace ethanol. TheDNA-containing columnwas
thenmoved to a clean 1.5-mLmicrocentrifuge tube, and 50 mL
of DNAase/RNAase free water (Qiagen) prewarmed to 55C
was applied to the column. The columns were incubated with
water for 2minutes and collected by centrifugation. The 50-mL
elutant was immediately reapplied to the column and recol-
lected by centrifugation to maximally recover and concentrate
the gDNA in a small end volume.
Whole Genome Ampliﬁcation
In the Repli-g Ultrafast WGA mini kit (Qiagen) a total input
of 10 ng of DNA from each DBS was used per reaction
according to the manufacturer’s protocol. Denaturation
buffer D1 was added to template gDNA, vortexed to mix,
and centrifuged to collect. The samples were incubated at
room temperature (approximately 22C) for 3 minutes. The
reaction was then neutralized by the addition of buffer N1.
A master mix containing reaction buffer and DNA poly-
merase was applied to the gDNA and incubated for 1.5
hours at 30C, followed by a heat inactivation step of 3
minutes at 65C. Samples were then moved into quality
analysis.
In the Genomeplex WGA Kit (Sigma-Aldrich, St. Louis,
MO) template DNA was fragmented by applying the 10
fragmentation buffer followed by an incubation at 94C for
4 minutes. The library preparation buffer and library stabi-
lization solution were added to the fragmented gDNA
template, vortexed to mix, and centrifuged to collect, fol-
lowed by 2-minute incubation at 95C. The sample was
cooled on ice and the library preparation enzyme was added.
The reactions were placed in a PCR thermocycler and
subjected to a cycle of 20 minutes at the following
temperatures in succession: 16C, 24C, and 37C, followed
by 5-minute 72C ﬁnal elongation step. Ampliﬁcation was
performed using the WGA DNA polymerase and ampliﬁ-
cation master mix provided. The reactions were cycled 14
times in a PCR thermocycler after denaturation at 95C for
3 minutes, denaturation at 94C for 15 seconds, and a 65C
5-minute anneal and extension step. Samples were moved
into quality analysis.jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 1 Extraction of gDNA and WGA from decades-old 3-mm blood spots assessed for quality, quantity, and molecular-weight spectra. A: The ﬂowchart
deﬁnes our current QC paradigm (gray) to assess sample quality, quantity, and integrity of blood spotederived gDNA samples compared with VAFE (black). The
dotted black line shows the ability of VAFE to assess all QC parameters simultaneously even after the initial extraction, enabling efﬁcient sample charac-
terization for entry into downstream genomic applications. B: Quantiﬁcation of total gDNA extracted from a single 3-mm blood spot using the QiaAmp Mini Kit
measured using 260/280 ratio of a Nanodrop (black bar) and the VAFE on the TapeStation (gray bar). The 260/280 ratio overestimates dsDNA, whereas VAFE
uses a ﬂuorescent Sybr dye to calculate concentration, which is only capable of intercalating in dsDNA, resulting in a more accurate quantiﬁcation. C: VAFE
quantiﬁcation of gDNA extracted from a single 3-mm blood spot before (gray bar) and after (dark bar) WGA. The WGA yields approximately 1 mg of dsDNA from
a starting template of approximately 10 ng. D: Slab gel analysis of gDNA integrity reveals that pre-WGA DNA is not detectable on the slab gel, whereas all post-
WGA samples are of high molecular weight comparable to reference DNA samples (275 and 12.5 ng) extracted from venous blood. The extracted gDNA spot (Q)
is run in parallel with the post-WGA ampliﬁcation (W) of the same template. E: Visualization of pre- and post-WGA blood spot samples using VAFE shows high-
molecular-weight DNA is extracted from the decades-old blood spot. This high-molecular-weight DNA (>48,500 bp) is enriched in the post-WGA sample.
F: Fluorescent electropherograms of the DNA extracted from a blood spot collected in 1975 and 1982. The pre-WGA DNA (black) contains high-molecular-
weight (7000 to 48,500 bp) DNA. In both blood spots the post-WGA (gray) sample shows an enrichment of heavy fragments, but the relative amount of
small to large fragments differs greatly between the samples, suggesting that samples must be evaluated for quality on an individual basis.
VAFE Quality Control of Genomic DNAQuantiﬁcationand Integrity Analysis of Genomic Samples
Sample quantiﬁcation was performed in parallel using the
traditional QC algorithm versus a ﬂuorescence-based VAFE
method.
The Traditional QC Algorithm
Two microliters of pre- and post-WGA DNA from each
sample was quantiﬁed using a 260/280 absorbance ratio onThe Journal of Molecular Diagnostics - jmd.amjpathol.orga Nanodrop1000 (ThermoFisher, Waltham, MA). After
quantiﬁcation, 2 mL of DNA was stored in a 0.2-mL sterile
PCR tube for visualization on a slab gel. To assess gDNA
integrity before and after WGA, 1% agarose/ethidium
bromide gel using Tris-acetate-EDTA buffer was prepared.
Samples reserved from quantiﬁcation were prepared by the
addition of 10 mL of sterile water and 3 mL of loading dye.
Samples were loaded pairwise onto the gel with two known
concentrations (275 and 12 ng) of reference gDNA extrac-
ted from venous blood. A total of 5 mL of Hyperladder I285
Klassen et al(Bioline, Taunton, MA) was used to identify samples of
high (>10 kb) molecular weight.
The VAFE QC Algorithm
A fresh 1-mL aliquot of the sample was added to 10 mL of
sample buffer, quantiﬁed, visualized, and qualitatively
assessed on the Agilent 2200 TapeStation. The DNA molec-
ular weight spectra were reviewed, and all data were saved and
stored for future reference and comparative analysis.
PCR Analysis
Pre and post-WGA gDNA fromDBSs of all ages was assessed
by quality PCR ampliﬁcation. Standard 50-mL PCRs using
Apex Taq Polymerase (Genesee Scientiﬁc, San Diego, CA)
were performed with oligonucleotide primers targeting known
polymorphisms that contained exons from ion channelopathy
genes. Amplicons ranging from 300 to 1000 bp in size were
generated using 1 mL of input DNA (concentration range, 0.6
to 12.5 ng/mL) using a PCR program with 10-minute initial
denaturation at 94C, followed by 40 cycles of 94C for 30
seconds, 56C for 1 minute, 72C for 1 minute, and a ﬁnal
elongation step of 10 minutes at 72C. A positive control
reaction using 12.5 ng/mL of reference DNA extracted from
venous blood was included for comparison. Reactions were
size resolved on a 2% agarose/ethidium bromide Tris-acetate-
EDTA gel using a 10-kb ladder for size comparison.
Sanger Sequencing
The individual PCRs that yielded a single 1000-bp amplicon
from the RYR2 gene were puriﬁed using the QiaQuick PCR
Puriﬁcation Spin Kit (Qiagen). Templates were quantiﬁed
according to the speciﬁcations of the vendor on the Nano-
drop1000, and approximately 10 to 15 ng of template was
submitted for commercial Sanger sequencing (GeneWiz,
South Plainﬁeld, NJ). The resulting traces were visually vali-
dated, and chromatograms were aligned pairwise with pre- and
post-WGA DBS data and compared across all samples.
Comparative Genome Hybridization Copy Number
Variant Analysis
We assessed the utility of post-WGA DBS samples for
comparative genomic hybridization (CGH) arrays for
detection of genomic copy number variation (CNV) using
our custom-designed, high-resolution epilepsy candidate
gene array (Agilent 019033). The array has even coverage
along the whole genome backbone and additional high-
density exomic probe coverage (approximately 3 to 5 probes
per exon) across roughly 250 ion channel genes, along with
additional monogenic epilepsy genes with variable density
coverage of intronic probes. All CGH experiments were
performed using the manufacturer’s recommended protocol
and the Agilent Genome Enzymatic Label Kit. Brieﬂy, 1.125286mg of each post-WGA sample and 1.125 mg of control female
reference gDNAwere digested with RsaI and AluI restriction
enzymes for 2 hours at 37C, followed by heat inactivation at
65C for 20 minutes. The complete digestion was conﬁrmed
visually by running 2 mL of each sample on a 1% agarose/
ethidium bromide Tris-acetate-EDTA gel. The remaining
digested DNA was subsequently puriﬁed and labeled with
either Cy-3-dUTP (reference DNA) or Cy-5-dUTP (post-
WGA DNA). DNA was hybridized for 40 hours at 65C
under constant rotation in a light impermeable hybridization
oven (Agilent Technologies). Arrays were then washed and
stabilized before image acquisition on the SureScan D
Scanner (Agilent Technologies). The resulting image was
imported into Agilent Feature Extraction Software version
10.7.3.1 (Agilent Technologies) and analyzed for ﬂuorescent
signal log ratio generating a feature extraction ﬁle for each
individual genome proﬁle. The feature extraction ﬁles were
analyzed in Genome Workbench (Agilent Technologies)
using the built-in ADM-2 detection settings and the default
aberration ﬁlter version 2. Data for this experiment and cor-
responding platform ﬁles can be viewed at http://www.ncbi.
nlm.nih.gov/geo (accession number GSE44249).
Results
VAFE Provides Superior Accuracy in the Measurement
of DBS-Derived DNA Concentration
The total DNA extracted from each DBS was quantiﬁed in
parallel using a spectrophotometer (ThermoFisher Nano-
drop1000) and a ﬂuorescence-based system (Agilent 2200
TapeStation) (Figure 1A). Both methods detected measur-
able amounts of nucleic acids in all samples, and there was
no deﬁnite correlation between the sample age and the DNA
concentration, which is in agreement with data reported
previously.17 However, a statistically signiﬁcant difference
was found in the total DNA per blood spot as measured by
individual platforms (40 to 384 ng per the Nanodrop1000
versus 12 to 49 ng per the Agilent 2200 TapeStation; t Z
3.68, P Z 0.002) (Figure 1B). We conﬁrmed measurement
accuracy by using high-molecular-weight gDNA standards
of known concentrations on both systems. We found that
both performed well when quantifying high-quality double-
stranded DNA (dsDNA). The sample detection limit was
>1 ng/mL by the Nanodrop1000 and >0.5 ng/mL by VAFE
(Supplemental Figure S1A). Using high-molecular-weight
quantitative PCR standards, we found that the minimal
concentration necessary for ﬂuorescence-based reliable
visual proﬁling of gDNA molecular-weight spectra was
2 ng/mL (Supplemental Figure S1B). These results support
our earlier observation15 that the quantiﬁcation based on
absorbance ratio tends to overestimate DNA concentration
in suboptimal or degraded samples. The ratiometric measure
provides an estimate of sample purity, but it is blind to the
nucleic acid integrity, length, or proportional representation
of single- versus double-stranded helices, both of which canjmd.amjpathol.org - The Journal of Molecular Diagnostics
VAFE Quality Control of Genomic DNAact as a template for WGA ampliﬁcation. In contrast, the
VAFE sample buffer contains a SYBR green-based ﬂuo-
rophore, which intercalates with dsDNA molecules,27 giving
an accurate measure of dsDNA below the concentration of
<100 ng/mL.VAFE Measures of Quantity and Quality Outperform
Traditional Platforms and Facilitate Systematic WGA
Ampliﬁcation of gDNA from Archived Neonatal DBS
Samples
A single 3-mm DBS averaged 26.3  13.1 ng of total gDNA,
an amount insufﬁcient for many commercial or diagnostic
high-throughput whole genome or whole exome sequencing or
structural variant proﬁling assays, which typically require
>1 mg of high-molecular-weight DNA to interrogate the entire
genome. To overcome this limitation, we performed WGA on
the archived DBSs using 10 ng of extracted blood spot DNA as
a template. The resulting ampliﬁed DNA samples were VAFE
quantiﬁed, and all demonstrated an increase in total DNA
amount (Figure 1C). Most samples (7 of 8) showed a 20 to 50
times increase, resulting in approximately 1 mg of total DNA
content. A single sample dated 1982 relatively under-
performed, and the ﬁnal total amount was 154 ng of gDNA.
Although sufﬁcient sample quantity is important, sample utility
critically depends on the proportional representation and
availability of DNA fragments of usable length. To assess the
integrity and molecular weight of the samples, pairs of the pre-
and post-WGA samples were run on a traditional agarose slab
gel in parallel with a 10-kb ladder and reference DNA extracted
from venous blood (Figure 1D). As expected, the DBS-
extracted original gDNA was not visible on the slab gel
because of the low concentration (approximately 1 to 3 ng/mL)
of DNA in these samples. However, the post-WGA samples
were clearly observed and ran at the same apparent molecular
weight as the reference venous bloodederived DNA. Notably,
none of WGA blood spots showed any discernible signs of
degradation smear at the lower size range.
The identical sample set was run on VAFE, which uses
microelectrophoresis of the DNA sample through a precast
gel tape using a high-molecular-weight ladder for size
comparison. We then compared the results between the two
systems. Unlike the slab gel, VAFE clearly shows a high-
molecular-weight band >15 kb in size in all of the pre-WGA
DNA extractions from decades-old blood spots. Analysis of
the post-WGA sample conﬁrmed that not only did the
ampliﬁcation produce substantially more dsDNA, but it also
occurred preferentially in the high-molecular-weight range,
and the post-WGA samples uniformly resembled the venous
bloodederived gDNA (Figure 1E). Individual samples were
then analyzed with regard to the size proﬁle of the DNA
fragments (Figure 1F). Unlike the agarose slab gel, the
VAFE clearly discriminated small but individually variable
and age-independent degradation in all samples, as evi-
denced by the presence of lower-molecular-weight DNAThe Journal of Molecular Diagnostics - jmd.amjpathol.orgfragments. The relative abundance of the high- versus lower-
molecular-weight fragments was also variable between
samples, suggesting that the pre- and post-ampliﬁcation
sample quality is better evaluated on an individual basis. In
summary, the integrated quantity and quality measures from
VAFE analysis deﬁne the integrity of archived DBS-derived
gDNA, providing a QC parameter that is predictive for
yielding high-molecular-weight gDNA after WGA.
VAFE-Established Sample Quality Conﬁrms Utility in
PCR, Sanger Sequencing, and CGH
Polymerase Chain Reaction
Our current QC paradigm for gDNA integrity involves an
experimental assessment of DNA utility because samples
may be variably visible on a traditional slab gel and the
established 260/280 absorbance ratioebased quantiﬁcation
method may overestimate the content and integrity of the
specimen.15 In contrast, VAFE can assess quality, quantity,
and integrity of a gDNA sample simultaneously using
a minimal volume of a discrete sample. This is extremely
important when samples are limited and is critical in retro-
spective archival postmortem molecular diagnostic autopsy
or research on genomic causality of sudden unexpected
death. We successfully PCR ampliﬁed all pre- and post-
WGA samples except for two samples that failed to
amplify two different amplicons. A 1975 DBS sample failed
to amplify the 300-bp amplicon of the 32nd exon of the RYR2
gene encoding the cardiac ryanodine receptor (Supplemental
Figure S2). However, we saw the 1000-bp amplicon for exon
37 in the same gene in this sample, suggesting that the WGA
DNA from 1975 was of sufﬁcient quality and quantity to act
as a template across the gene region. Similarly, the WGA
sample from the 1986 blood spot failed to amplify the 1000-bp
exon in HTR2A while producing a faint 1000-bp amplicon
for RYR2 exon 37 and a robust 300-bp amplicon for exon 32
in RYR2 (Supplemental Figure S2). Our quality PCR stan-
dard operating procedure requires that any failed amplicons
be repeated with the failed DNA sample to differentiate
failure due to intrinsic (sample quality) versus extrinsic
(technical ﬂaw) factors (Figure 1A). All initially failed
amplicons ampliﬁed on successive quality PCR assays, thus
eliminating concerns regarding sample quality. It was reas-
suring to know that the inherently low concentration of the
freshly extracted gDNA is sufﬁcient to produce robust PCR
ampliﬁcation. This ensures that genetic variation identiﬁed
in the WGA samples can be validated in the original blood
spot gDNA to remove any potential false-positive variants
that result from the WGA.
Sanger Sequencing
The 1000-bp fragment from RYR2 exon 37 was the template
for commercial Sanger sequencing reactions (Supplemental
Figure S3). All pre- and post-WGA blood spot samples
were successfully sequenced with clear bp calls from the
chromatogram. We consistently observed higher background287
Klassen et alsignal in pre-WGA samples in the <250-bp range; however,
this background noise was insufﬁcient to prevent the
identiﬁcation of heterozygous half height chromatogram
peak reductions. In summary, our work supports the liter-
ature10e12,28 in that gDNA from decades-old infantile
blood spots can be used successfully in traditional medical
genetic resequencing studies to detect single-nucleotide
polymorphism (SNP) variants that possibly contribute to
the risk of epilepsy and SUDEP.
Comparative Genomic Hybridization
The enzymatic digestion of the post-WGA DNA was
successful, showing fragment size and distribution similar to
the digested reference DNA (Supplemental Figure S4A), with
the notable absence of high-molecular-weight undigested
DNA. After puriﬁcation and labeling, all of the post-WGA
samples met QC requirements for the microarray, and hy-
bridization was performed. The results were visualized
(Supplemental Figure S4B), and all 8 individual arrays
underwent successful feature extraction. The QC of the array
data revealed that all arrays had a moderate background signal
and a signal to noise ratio requiring visual assessment of probe
distribution. Seven of the eight arrays passed QC. The 1978
post-WGA sample had an unacceptably high number of
nonuniform outlier probes.Using theADM-2 default algorithm
in Genomic Workbench (Agilent), CNVs were detected in all
samples. Because we performed our comparative hybridization
blind to sex using a female reference DNA, we were able to use
the CNV algorithm to identify male samples by comparing the
copy number of the X chromosome. Female samples with XX
genotype showed discreet small CNVs across the chromosome,
whereas male XY samples showed a relative loss of X chro-
mosome consistent with their XY genotype (Supplemental
Figure S4C). These results support the literature in that post-
WGA ampliﬁed gDNA from DBS sources is amenable to
high-throughput array-based technologies.19,20,24,28 Unequal
whole genome ampliﬁcation needs to be considered, especially
in degraded samples.25 However, previous studies comparing
pre- and post-WGA gDNA samples from neonatal blood spots
similar to ours reported >99% SNP concordance between
ampliﬁed and native samples.24
Failed VAFE QC Informs Suboptimal gDNA Extractions
from DBS
The previously extracted suboptimal samples that under-
performed in our traditional QC paradigm were simulta-
neously analyzed with VAFE to compare and deﬁne the
informative value of each platform and the reasons for sample
failure. The 260/280 absorbanceebased measurement sug-
gested 6.8 to 11.8 ng/mL of gDNA across the four samples.
However, the low concentration of the initial template was
below the limit of visualization on the traditional agarose gel,
indicating a lower gDNA concentration than indicated by the
absorbance-based quantiﬁcation. We performed WGA using
two separate systems using different ampliﬁcation strategies.288The Repli-g Ultrafast WGA kit uses a multidisplacement
ampliﬁcation method, resulting in long DNA fragments (>10
kb), whereas the Genomeplex WGA kit uses the omniplex
method producing short (500 bp) DNA fragments. The WGA
kit using the Repli-g system augmented the total gDNA
amount (Supplemental Figure S5A), and subsequent slab
gel visualization indicated the existence of the high-
molecular-weight gDNA in the presence of some degrada-
tion as evidence by smear (Supplemental Figure S5B). The
GenomeplexWGA system only produced a moderate increase
in DNA content (71.6  29.3 ng total, nZ 4) compared with
the Repli-g system (1024  239 ng total, nZ 4) when using
the same input template. Following our traditional QC
protocol, the quality PCR was performed targeting amplicons
ranging in size from 250 to 1000 bp in parallel on pre- and
post-WGA samples. However, it failed across all samples
except for the 250-bp fragment of the RYR2 gene generated on
the pre-WGA blood spot extracted DNA (Supplemental
Figure S5C). Examination of the suboptimal samples pre-
and post-WGA by VAFE revealed lesser than traditionally
measured quantity of the starting template. Importantly, the
electropherograms produced by the ﬂuorescent signal clearly
showed the substantial degradation of the initial gDNA
template (Supplemental Figure S5, D and E). Both WGA
systems tested increased the total gDNA amount after ampli-
ﬁcation. As predicted by the kit method, the Genomeplex
WGA samples were composed of <500-bp DNA fragments.
In contrast, most DNA molecules produced using the Repli-g
system remained of low molecular weight, ranging in size
from 400 to 4000 bp, indicating a lesser quality, fragmented
input template from suboptimal DBS gDNA extractions
(Supplemental Figure S5E). These smaller post-WGA frag-
ments subsequently failed in downstream applications as
demonstrated by the failed quality PCR. This outcome is also
in agreement with our earlier observations.16 Analysis of the
suboptimal samples showed that VAFE clariﬁes important
parameters related to sample quality, quantity, and integrity to
be considered before proceeding with further costly and time-
consuming downstream genomic investigation.Discussion
The DBSs collected within the framework of neonatal
screening program are an attractive alternative source of
gDNA because of their low cost and ease of collection and
long-term storage.17,18,22,29 The DBSs preserved and pro-
tected in the neonatal biobanks represent a multigenerational
archive of populations and offer an unparalleled opportunity
to assess both personal and population-based proﬁles of
genetic variation.20,21,30 Moreover, they may be the only
resource for a personal genomic proﬁle in cases of sudden
unexpected death.4,5,12,13,15,23,31 However, DBSs are a ﬁnite
reserve. They need to be judiciously allocated to projects
and used with utmost efﬁciency to maximize and extend the
possibilities for use of individual samples.8,10,29jmd.amjpathol.org - The Journal of Molecular Diagnostics
VAFE Quality Control of Genomic DNAThe VAFE is an efﬁcient QC technology that is ideally
suited for projects that work with samples of minimal
quantity or uncertain quality. Our data indicate that VAFE
delivers reliable quantiﬁcation of precious, much diluted
gDNA samples extracted from decades-old DBS samples.
An additional unique attribute of this novel system is the
capacity to provide complementary information simulta-
neously through the visualization of sample quality, integ-
rity, and molecular-weight spectrum from a single microliter
of gDNA. This platform demonstrated that gDNA extracted
from decades-old infantile blood spots is composed of small
fragmented DNA (<200 bp) and high-molecular-weight
(>15 kb) molecules (Figure 1F), and if it is sufﬁcient in
quality and integrity, it is amenable to WGA ampliﬁcation,
resulting in large amounts (>1 mg) of predominantly high-
molecular-weight DNA.19 The VAFE-based QC can iden-
tify suboptimal samples early in sample processing, and our
follow-up experiments conﬁrmed and correlated the failed
QC with their limited utility in downstream applications,
including the impervious PCR (Supplemental Figure S4C).
We also observed that the quality or utility of the DNA did
vary across individual blood spots,30,32,33 indicating the
need for systematic integration of reliable, efﬁcient, and
highly informative QC into sample preparation and assess-
ment to maximize the quality and reliability of ﬁnal
genomic data and use of resources.34,35
We have previously demonstrated a working effective
QC paradigm that uses commonly available, albeit indirect
and somewhat imprecise, methods for characterization of
the gDNA properties extracted from alternative tissues,
including DBSs.15 However, visual automated ﬂuorescent
electrophoresis represents a new-generation QC that de-
livers direct visualization and accuracy and that considers
the imperative for minimal sample consumption. Results of
this study will be applicable for projects that work with
ﬁnite and limited DNA samples expected to deliver diag-
nostically accurate genomic data.
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